ABSTRACT
Purpose To study the expression and significance of Gal-3 and BCL-2 in ulcerative colitis (UC).Methods 64 cases of patients diagnosed as UC in the Department of Digestive Dseases were selected as the observation group in our hospital from August 2014 to December 2015.And 50 healthy volunteers were selected as control group.The expression levels of BCL-2 and Gal-3 in the two groups were detected,and the correlation between and UC and between BCL-2 and Gal-3 was studied.Results The positive rate of Gal-3 in the control group was 100％,higher than 37.5％ in the observation group(x2 =48.142,P ＜0.001).The positive rate of BCL-2 in the control group was 20％,which was lower than that in the observation group of 90.62％ (x2 =58.171,P ＜ 0.001).The Gal-3 positive rate of UC Grade Ⅰ was higher than UC Grade Ⅱ (x2 =5.539,P =0.019),The Gal-3 positive rate of UC Grade Ⅰ was higher than UC Grade Ⅲ (x2 =4.532,P =0.033),The Gal-3 positive rate of UC Grade Ⅲ was lower than UC Grade Ⅱ (x2 =0.183,P=0.669).The BCLo2 positive rate of UC Grade Ⅰ was lower than UC Grade Ⅱ (x2 =5.539,P=0.019).The BCL-2 positive rate of UC Grade Ⅰ was lower than UC Grade Ⅲ (x2 =6.098,P=0.014).The BCL-2 positive rate of UC Grade Ⅲ was higher than UC Grade Ⅱ (x2 =0.511,P =0.475).BCL-2 and Gal-3 expression was not related to gender,age and disease duration (P ＞ 0.05).The expression of BCL-2 and Gal-3 was not correlated.Conclusion The expression level of BCL-2 in UC is higher than that in normal colorectal mucosa.The expression level of Gal-3 is lower than that of normal colorectal mucosa.The expression of UC has no effect on sex,age and course of disease,and it could be used as the prediction standard of UC.
ABSTRACT
PURPOSE: The objective of this study was to determine Bcl-2 expression in localized prostate cancer and its potential role as a predictive factor for biochemical recurrence (BCR). MATERIALS AND METHODS: This study included 171 Korean patients with newly diagnosed adenocarcinoma of the prostate who underwent radical prostatectomy (RP) without neoadjuvant therapy at a single center between February 2005 and May 2009. RP specimens obtained from these patients were analyzed for the expression of Bcl-2 using tissue microarray. The values of Bcl-2 and other clinicopathologic factors were evaluated. Statistical analysis was performed with contingency table analysis, chi-square tests, and a Cox proportional hazard model. RESULTS: Bcl-2 expression was immunohistologically-confirmed in 42 patients (24.6%). Bcl-2 expression was not associated with conventional clinicopathologic factors. Bcl-2 negative patients had a significantly longer mean BCR-free survival than Bcl-2-positive patients (p=0.036). Among several variables, a high Gleason score in the RP specimen (> or =8), extraprostatic extension, seminal vesicle invasion (SVI), lymphovascular invasion (LVI), and Bcl-2 expression were significant predictors of BCR based on univariate analysis. Multivariate Cox proportional hazards analysis revealed that BCR was significantly associated with a high prostate specific antigen level (p=0.047), SVI (p<0.001), a positive surgical margin (p=0.004) and Bcl-2 expression (p=0.012). CONCLUSION: Bcl-2 expression in RP specimens is associated with a significantly worse outcome, suggesting a potential clinical role for Bcl-2. Post-operative Bcl-2 could be a significant predictor of outcome after RP.